Health
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
SHANGHAI, March 7, 2024 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Admi...
2024-03-08 10:00
1469
Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China
WUXI, China, March 7, 2024 /PRNewswire/ -- Silk Road Medical (NASDAQ: SILK), a medical device company based inCalifornia USA and Genesis MedTech Group have signed an exclusive distribution agreement to introduce the TCAR® core products, ENROUTE® Transcarotid Neuroprotection System and ENROUTE® T...
2024-03-08 10:00
1505
Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry
WUHAN, China, March 7, 2024 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management systems. After passing rigorous reviews on all the items of...
2024-03-07 22:00
1556
Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions
HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market inChina, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developi...
2024-03-07 15:04
1471
Puritan's Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands
NEW YORK, March 6, 2024 /PRNewswire/ -- As global health awareness has increased, there has been a notable shift in people's focus from "treatment" to "prevention" of diseases. OnDecember 4, 2023, the International Self-Care Foundation and the Dietary Guidance Committee of the Chinese Aging Well ...
2024-03-06 21:37
1284
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
--CUSP06 is a CDH6-directed Antibody-Drug Conjugate (ADC) with a differentiated profile and potentially best-in-class activity-- NEW YORK, March 6, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innova...
2024-03-06 21:00
1241
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC
HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparingCadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with ...
2024-03-06 18:07
1943
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical stud...
2024-03-06 08:59
3097
Datasea Expects Approximately 1,128% Revenue Growth in 2024
BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology inChina and the US, issued guidance today for expecting a revenue o...
2024-03-05 23:45
3000
Laifen Launches the Laifen Wave Electric Toothbrush, a Revolutionary New Oral Health and Wellness Experience
Laifen's Newest Self-Care Innovation is Now Available to Purchase in the U.S.
HONG KONG, March 5, 2024 /PRNewswire/ -- Laifen
2024-03-05 22:00
1665
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environ...
2024-03-05 21:00
1675
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
GAITHERSBURG, Md., March 5, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2024-03-05 21:00
2810
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
TAIPEI, March 4, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-opera...
2024-03-05 06:55
1578
ACROBiosystems Launches New Initiative to Support Cell and Gene Manufacturers
NEWARK, Calif., March 4, 2024 /PRNewswire/ -- ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative to supportex vivo cell manufacturing and manufacturers of innovative cell and gene therapies. I...
2024-03-04 22:00
1359
Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024
- Showcases brain imaging analysis technology with key products Neurophet AQUA and Neurophet SCALE PET - Aims to commercialize ARIA analysis and amyloid-positive prediction technology SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company f...
2024-03-04 22:00
1566
KCI, a subsidiary of Samyang Group, won 'Platinum Medal' in EcoVadis ESG Rating, Ranked in the Top 1% worldwide
* Evaluated firstly as a L'Oreal partner in 2013 and achieved the highest rating in 11 years * Efforts to establish an ESG committee, reinforce labor and human rights management, and improve management of partners SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Samyang Group announced that ...
2024-03-04 21:30
1481
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has officially approved the YOLT-2...
2024-03-04 20:00
738
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease
- CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum's disease treatment. NEW TAIPEI CITY, March 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orp...
2024-03-04 07:00
1959
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
SHANGHAI, March 1, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that today the National Medical Products Administration ("NMPA") ofChi...
2024-03-01 21:50
2083
111 to Announce Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results- Conference Call to Follow
SHANGHAI, March 1, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2024-03-01 17:00
2723
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 292 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
[Picked up by 279 media titles]
2024-11-08 20:11
Most Read
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10154
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7512
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6227
